The Morisky Medication Adherence Scale (MMAS-8) and the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) are both validated self-report tools used to assess medication adherence in chronic diseases, but they serve different purposes. The MMAS-8 is considered a lagging metric because it measures past adherence behaviors and outcomes (e.g., whether patients have already missed doses or deliberately skipped medications), reflecting historical performance. In contrast, the SEAMS is a leading metric because it assesses patients’ confidence (self-efficacy) in managing future medication-taking tasks, predicting potential adherence challenges before they manifest.

As a lagging metric, MMAS-8 is diagnostic, confirming nonadherence after it occurs. It’s useful for assessing the extent of adherence problems and correlating them with clinical outcomes (e.g., poor blood pressure control in hypertension). However, it doesn’t predict future adherence or identify why barriers exist, limiting its proactive utility. For example, a patient scoring low on MMAS-8 (e.g., 4/8) has already exhibited nonadherence, but the tool doesn’t explain underlying confidence or capability issues.

As a leading metric, SEAMS is predictive, identifying patients at risk of nonadherence before it occurs. For example, a patient with low confidence in managing side effects (SEAMS item #11) is likely to skip doses in the future, allowing clinicians to intervene proactively with education or regimen adjustments. Its focus on self-efficacy makes it actionable for tailoring interventions to boost confidence.

Complementary Roles and WHO Barrier Mapping • Lagging vs. Leading Synergy: MMAS-8 and SEAMS complement each other in addressing WHO patient-related barriers:

• MMAS-8 (Lagging): Confirms past nonadherence, quantifying the extent of barriers like forgetfulness (e.g., >50% prevalence in hypertension, AlGhurair et al., 2012) or intentional nonadherence due to low motivation or beliefs. It’s reactive, identifying patients who have already struggled.
​
• SEAMS (Leading): Predicts future nonadherence by assessing confidence deficits that underpin these barriers. For instance, low SEAMS scores on remembering doses (#6) predict forgetfulness, while low scores on managing side effects (#11) predict motivational issues, as seen in myasthenia gravis patients (Wang et al., 2024, OR=1.194 for self-efficacy).

​A Path to Better Adherence
​For researchers and clinicians tackling medication adherence, MMAS-8 and SEAMS are a perfect pair. MMAS-8, the lagging metric, diagnoses past adherence failures, shining a light on barriers like forgetfulness and low motivation. SEAMS, the leading metric, predicts future risks by assessing self-efficacy, empowering proactive solutions. Together, they map WHO patient-related barriers comprehensively, offering actionable insights for your rheumatoid arthritis study in Sudan. By using MMAS-8 to identify nonadherent patients and SEAMS to target confidence deficits, you can design interventions—like education or simplified regimens—that improve outcomes despite economic challenges.

​Let’s leverage these tools to help patients stay on track and reduce flares worldwide! If you’re ready to integrate these into your study, check out the resources or reach out for support.
​


​

​

​

Medication non-adherence is a pervasive challenge in healthcare, contributing to poor health outcomes, increased hospitalizations, and rising costs. The World Health Organization (WHO) identifies five dimensions of barriers to adherence: patient-related, condition-related, therapy-related, health system/healthcare team-related, and social/economic factors. To effectively address non-adherence, clinicians and researchers must first identify whether a patient is non-adherent and whether their non-adherence is intentional (deliberate) or unintentional (e.g., due to forgetfulness). The Morisky Medication Adherence Scale (MMAS-8) is a widely used, validated tool to assess adherence and distinguish between intentional and unintentional non-adherence. By combining MMAS-8 with other validated scales, healthcare providers can pinpoint specific WHO barriers and tailor interventions accordingly. This blog explores how to use the MMAS-8 to assess adherence and leverage complementary scales to identify WHO barriers.
Step 1: Assessing Adherence with the MMAS-8
The MMAS-8 is an 8-item, self-report questionnaire designed to measure medication adherence, particularly for chronic conditions like hypertension, diabetes, or asthma. It is simple to administer, takes about 2–3 minutes, and is validated across diverse populations. The scale includes questions that assess both unintentional and intentional non-adherence, making it an ideal starting point.
How the MMAS-8 Works
• Structure: Seven yes/no questions and one 5-point Likert scale question.
• Scoring: Each item is scored (0 or 1 for yes/no; 0–1 for the Likert scale). Total scores range from 0 to 8:
• High adherence: Score = 8
• Medium adherence: Score = 6 - <8
• Low adherence: Score < 6
• Distinguishing Intentional vs. Unintentional Non-Adherence:
• Unintentional: Items like “Do you sometimes forget to take your pills?” or “Did you not take any of your medicine over the past weekend?” reflect forgetfulness or carelessness.
• Intentional: Items like “Have you ever cut back or stopped taking your medication without telling your doctor because you felt worse?” or “When you feel like it’s not working, do you stop taking it?” indicate deliberate choices.
Using MMAS-8 in Practice
Imagine a patient with type 2 diabetes who scores 4 on the MMAS-8, indicating low adherence. Their responses show they often forget to take their medication (unintentional) but also stop taking it when they feel better (intentional). This dual insight guides the next steps: addressing forgetfulness (e.g., reminders) and exploring reasons for intentional non-adherence (e.g., beliefs or side effects).

​Step 2: Mapping WHO Barriers with Validated Scales Once non-adherence is identified and classified as intentional or unintentional, clinicians can use targeted scales to explore the underlying WHO barriers. Below, we outline each dimension, corresponding scales, and how they complement MMAS-8 findings.
1. Patient-Related Factors
These include knowledge, beliefs, motivation, or psychological factors. Intentional non-adherence often stems from negative beliefs or low motivation, while unintentional non-adherence may relate to cognitive issues.
• Validated Scale: Beliefs about Medicines Questionnaire (BMQ)
• Purpose: Measures beliefs about medication necessity and concerns about side effects.
• How It Helps: If the MMAS-8 indicates intentional non-adherence (e.g., stopping medication due to feeling worse), the BMQ can reveal if this is due to concerns about side effects or low perceived necessity. For example, a patient who believes their diabetes medication is harmful may score high on BMQ-Concerns, guiding interventions like patient education.
• Example: A patient with a high BMQ-Concerns score might benefit from counseling to address misconceptions about medication risks.
• Alternative Scale: Medication Adherence Self-Efficacy Scale (MASES)
• Purpose: Assesses confidence in adhering to medication regimens.
• How It Helps: For unintentional non-adherence (e.g., forgetting doses), low MASES scores may indicate low self-efficacy, suggesting interventions like adherence aids or skill-building.
2. Condition-Related Factors
The nature of the disease (e.g., asymptomatic conditions, chronicity) can affect adherence. For example, patients with asymptomatic hypertension may intentionally skip doses due to a lack of perceived need.
• Validated Scale: Patient Activation Measure (PAM)
• Purpose: Assesses patients’ knowledge, skills, and confidence in managing their condition.
• How It Helps: A low PAM score in a patient with low MMAS-8 adherence may indicate poor understanding of their condition’s severity, contributing to intentional non-adherence. For instance, a hypertensive patient may not see the need for daily medication if they feel fine.
• Example: A low PAM score could prompt disease-specific education to improve condition awareness and adherence.
• Alternative: Disease-specific scales (e.g., Asthma Control Test for asthma) can assess how symptom burden or disease control affects adherence.
3. Therapy-Related Factors
Complex regimens, side effects, or long treatment duration can lead to both intentional (e.g., stopping due to side effects) and unintentional (e.g., missing doses due to complexity) non-adherence.
• Validated Scale: Treatment Satisfaction Questionnaire for Medication (TSQM)
• Purpose: Measures satisfaction with medication, including side effects, convenience, and effectiveness.
• How It Helps: If MMAS-8 shows intentional non-adherence, a low TSQM score for side effects or convenience may explain why. For example, a patient stopping their medication due to gastrointestinal side effects might score low on TSQM-Side Effects.
• Example: Simplifying the regimen or switching medications could address low TSQM scores and improve adherence.
• Alternative: Adherence to Refills and Medications Scale (ARMS) can further explore regimen complexity or refill issues.
4. Health System/Healthcare Team-Related Factors
Poor provider communication, limited access to care, or lack of trust can hinder adherence. These may contribute to intentional non-adherence (e.g., distrust in provider advice) or unintentional (e.g., inability to access refills).
• Validated Scale: Health Care Climate Questionnaire (HCCQ)
• Purpose: Assesses patient perceptions of provider support and communication.
• How It Helps: If MMAS-8 indicates low adherence, a low HCCQ score may suggest poor provider-patient relationships, prompting interventions like shared decision-making or improved communication.
• Example: A patient with a low HCCQ score might benefit from regular follow-ups with a trusted provider to build rapport.
• Alternative: Primary Care Assessment Survey (PCAS) evaluates access and continuity of care, which can uncover system-level barriers.
5. Social and Economic Factors
Cost, social support, health literacy, or cultural beliefs can drive non-adherence. For example, financial barriers may lead to intentional dose-skipping, while low social support may cause unintentional lapses.
• Validated Scale: Social Support Survey (SSS)
• Purpose: Measures perceived social support for health behaviors.
• How It Helps: A patient with unintentional non-adherence on MMAS-8 and low SSS scores may lack support for medication routines, suggesting interventions like involving family or community resources.
• Example: Connecting a patient with a support group could improve adherence if SSS scores are low.
• Alternative: Medication Access and Adherence Tool (MAAT) assesses cost-related barriers, particularly in low-resource settings.

​Step 3: Integrating Findings for Tailored Interventions with the MAAP In the blog’s Step 3, we discussed integrating findings from the Morisky Medication Adherence Scale (MMAS-8) with validated scales to map barriers to medication adherence across the five WHO dimensions and design tailored interventions. Here, we expand on this by incorporating the Medication Adherence Assessment Protocol (MAAP), a structured approach that can complement the MMAS-8 and other scales to systematically address adherence barriers, particularly for the social and economic dimension, but also applicable across all dimensions. The MAAP, while not as commonly referenced as scales like the BMQ or TSQM, is a framework used in some clinical and research settings to assess and address adherence barriers comprehensively. Below, we discuss how the MAAP can be integrated into Step 3 to enhance the intervention process.
What is the MAAP?
The Medication Adherence Assessment Protocol (MAAP) is a structured, multi-step process designed to assess medication adherence, identify barriers, and guide interventions. It typically involves:
• Assessment: Using standardized tools (like MMAS-8) to measure adherence and classify it as intentional or unintentional.
• Barrier Identification: Pinpointing specific barriers across the WHO dimensions through patient interviews, questionnaires, or validated scales.
• Intervention Planning: Developing tailored strategies based on identified barriers, often involving interdisciplinary collaboration.
• Follow-Up: Monitoring adherence over time to evaluate intervention effectiveness.
The MAAP is flexible and can incorporate various validated scales, making it ideal for integrating MMAS-8 findings with tools like the Beliefs about Medicines Questionnaire (BMQ), Patient Activation Measure (PAM), Treatment Satisfaction Questionnaire for Medication (TSQM), Health Care Climate Questionnaire (HCCQ), and Social Support Survey (SSS). It emphasizes patient-centered care and iterative refinement of interventions.

Step 1: Check for Peer-Reviewed Validation Studies
The first indicator of a validated assessment is the presence of peer-reviewed studies confirming its reliability and validity. Look for published research in reputable journals (e.g., PubMed, JAMA) that detail the assessment’s development and testing.

Step 2: Evaluate Reliability Metrics
A validated assessment should provide quantifiable evidence of consistency. Check for metrics such as internal consistency (e.g., Cronbach’s alpha ≥ 0.7) or test-retest reliability, which measure how reliably the tool produces the same results under consistent conditions.

Step 3: Assess Construct and Convergent Validity
Validation requires proof that the assessment measures what it intends to and aligns with established tools. Look for evidence of construct validity (does it measure adherence effectively?) and convergent validity (does it correlate with other validated measures?).

Step 4: Review Population Diversity in Testing
A truly validated assessment should be tested across diverse demographics, including age, gender, ethnicity, and geographic regions. This ensures generalizability.

Step 5: Seek Independent Replication
Validation is strengthened when independent studies replicate the original findings. Search for research from multiple sources confirming the assessment’s effectiveness.

Why It Matters
Using unvalidated assessments can lead to AI models that misclassify patient data—such as overestimating medication adherence, as seen in a 2022 case where an AI tool for opioid prescriptions contributed to overdoses due to flawed data. Validated tools mitigate these risks, ensuring AI enhances healthcare analytics, telehealth, and personalized medicine safely.

The Morisky Medication Adherence Scale (MMAS) has become a cornerstone in healthcare for assessing patient adherence to prescribed medication regimens. Renowned for its reliability, validity, and global applicability, the MMAS is not only synonymous with medication adherence but also an ideal tool for training AI learning models to enhance patient outcomes. This blog explores why the Morisky Scale is a gold standard in adherence science and how its structured, behavior-focused design makes it perfect for AI model training in healthcare.
The Morisky Scale: A Gold Standard in Medication Adherence
Developed by Dr. Donald E. Morisky, the MMAS began as a four-item questionnaire (MMAS-4) in 1986, designed to evaluate adherence to antihypertensive medications. It evolved into the more comprehensive MMAS-8, an eight-item scale that captures nuanced reasons for non-adherence across diverse patient populations and conditions, including diabetes, hypertension, HIV, and cancer. With over 32,000 citations and validation in over 90 countries, the MMAS is trusted by major pharmaceutical companies like Novartis and Pfizer, as well as healthcare providers worldwide.
The MMAS stands out due to its:
• Simplicity: Its concise, structured questions (seven yes/no and one Likert-scale question) make it easy to administer in clinical and research settings.
• Behavioral Focus: The scale identifies specific reasons for non-adherence, such as forgetting doses, stopping medication when feeling better, or skipping doses due to side effects.
• Global Validation: Independently validated across various diseases, languages, and cultures, the MMAS ensures consistent and reliable results.
• Actionable Insights: It categorizes adherence as low, medium, or high, enabling healthcare providers to create targeted interventions.
These qualities make the MMAS the go-to tool for measuring medication adherence, a critical factor in managing chronic diseases and improving health outcomes.
Why the Morisky Scale is Ideal for Training AI Learning Models
The integration of artificial intelligence (AI) in healthcare is transforming how we address challenges like medication non-adherence, which affects up to 50% of patients with chronic conditions. The MMAS’s structured design and robust validation make it an exceptional dataset for training AI learning models. Here’s why:
1. Structured and Quantifiable Data
The MMAS provides clear, quantifiable outputs (adherence scores) based on patient responses to its eight questions. This structured format is ideal for machine learning models, which thrive on consistent, well-organized data. For example, the MMAS-8 score (ranging from 0 to 8) can be used to train AI algorithms to predict adherence levels and identify at-risk patients. The binary (yes/no) and ordinal (Likert-scale) responses are easily encoded for AI processing, enabling models to analyze patterns in adherence behavior.
2. Behavioral Insights for Predictive Modeling
The MMAS captures specific reasons for non-adherence, such as forgetfulness or intentional discontinuation due to side effects. These behavioral insights allow AI models to go beyond simple predictions and identify underlying causes of non-adherence. For instance, an AI model trained on MMAS data could predict that a patient who frequently forgets doses might benefit from reminders via a health app or telehealth solution. This makes the MMAS a powerful tool for developing personalized medicine interventions.
3. Extensive Validation for Robust AI Training
The MMAS’s global validation across diverse conditions (e.g., type 2 diabetes, osteoporosis, chronic pain) and populations ensures that AI models trained on its data are generalizable. A 2017 systematic review found that the MMAS-8 has acceptable internal consistency (Cronbach’s α of 0.67 for diabetes and 0.77 for osteoporosis) and good convergent validity with other adherence measures. This reliability minimizes bias in AI training datasets, ensuring models produce accurate and trustworthy predictions.
4. Scalability for Large-Scale AI Applications
With its use in over 90 countries and translations into 80 languages, the MMAS provides a scalable dataset for training AI models across global healthcare systems. This is particularly valuable for health tech startups and healthcare analytics companies developing AI-driven tools for population health management. The MMAS’s widespread adoption ensures that AI models can be applied to diverse patient demographics, from rural clinics in Bhutan to urban hospitals in the U.S.
5. Integration with Digital Health Technologies
The MMAS aligns seamlessly with digital health tools like remote patient monitoring, mhealth, and telemedicine. AI models trained on MMAS data can be integrated into these platforms to provide real-time adherence monitoring and personalized interventions. For example, a wearable health device could use an AI model to analyze MMAS responses and send tailored reminders to patients, improving adherence rates. The MMAS’s compatibility with health informatics makes it a critical asset for AI-driven virtual care.
6. Support for Ethical AI Development
Training AI models requires adherence to ethical standards, including data fidelity and proper licensing. The MMAS is a proprietary tool, and its use is governed by strict licensing agreements through MMAR, LLC. This ensures that AI models trained on MMAS data maintain fidelity to the original validated structure, reducing the risk of misinterpretation or misuse. The mandatory Ξxpert training for MMAS users further ensures that AI developers understand the scale’s nuances, enhancing the ethical deployment of AI in healthcare.